NCT06851429

Brief Summary

Ovarian cancer remains the deadliest gynecologic malignancy, with poor survival rates largely due to late-stage diagnosis. Early detection is crucial, yet no universally accepted screening method exists. Current imaging techniques and biomarkers, such as CA-125, have limitations in specificity and sensitivity. This study aims to develop and evaluate a deep learning-based computer-aided diagnosis tool (CAT-OV), for ovarian cancer detection using CT imaging. The system integrates a Body Part Regression (BPR) model for pelvic localization and a Multiple Instance Learning (MIL) ensemble classifier for cancer prediction. The model was trained and validated using retrospective datasets from Taiwan, the United States, and a nationwide real-world cohort. Stringent preprocessing and quality control measures were implemented to enhance model accuracy. Results highlight the potential of AI-driven CT screening in improving early detection, though further validation is needed for clinical adoption.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
12,578

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2022

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 7, 2025

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

February 24, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 28, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2025

Completed
Last Updated

February 28, 2025

Status Verified

February 1, 2025

Enrollment Period

2.4 years

First QC Date

February 24, 2025

Last Update Submit

February 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Performance of a deep learning-based computer-aided diagnosis tool (CAT-OV) for identification of primary ovarian cancer on CT

    Sensitivity, Specificity, Accuracy, PPV, NPV, AUC

    Perioperative/Periprocedural 180 days

Study Arms (2)

control group

The control group included both benign ovarian tumors and an enriched dataset.

case group

ovarian cancer

Eligibility Criteria

Age20 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPatients were included if they had undergone a CT scan within 180 days prior to ovarian surgery for histopathological evaluation.
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Women who have undergone a CT scan.

You may qualify if:

  • Age ≥ 20 years old.
  • Female
  • undergone a CT scan
  • undergone a CT scan within 180 days prior to ovarian surgery for histopathological evaluation.

You may not qualify if:

  • Age \< 20 years old.
  • Non-female
  • Non-CT imaging
  • Incorrect image orientation
  • Number of slices \< 10
  • Slice thickness \>10 mm or \< 1 mm
  • Unsuccessful DICM-to-NIfTI
  • Pelvic subvolume extraction failed
  • Non-contrast CT scans
  • Metallic artifacts
  • Inconclusive cases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chang Gung Memorial Hospital

Taoyuan, Guishan District, 333, Taiwan

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

February 24, 2025

First Posted

February 28, 2025

Study Start

September 1, 2022

Primary Completion

February 7, 2025

Study Completion

February 28, 2025

Last Updated

February 28, 2025

Record last verified: 2025-02

Locations